Rapid Update 3- August 2017: Type 2 diabetes: potential cardiovascular benefits with the SGLT2 inhibitor canagliflozin but with a greater risk of amputation

This content is available to authorised users working in organisations that subscribe to ScriptSwitch only. Authorised users need to be logged in to read this content.

Healthcare professionals working in organisations that subscribe to ScriptSwitch may register to request access – please submit your details via the ‘register’ link at the top of this page.

Liraglutide: Cardiovascular outcome data in type 2 diabetes (Aug-16)

This content is available to authorised users working in organisations that subscribe to ScriptSwitch only. Authorised users need to be logged in to read this content.

Healthcare professionals working in organisations that subscribe to ScriptSwitch may register to request access – please submit your details via the ‘register’ link at the top of this page.

Type 2 Diabetes: cohort study finds that compared with other antidiabetic drugs, sitagliptin and saxagliptin do not increase the risk of heart failure (May-16)

This content is available to authorised users working in organisations that subscribe to ScriptSwitch only. Authorised users need to be logged in to read this content.

Healthcare professionals working in organisations that subscribe to ScriptSwitch may register to request access – please submit your details via the ‘register’ link at the top of this page.

Updated NICE guidance on Type-2 Diabetes – recommendations on drug treatments (Jan-16)

This content is available to authorised users working in organisations that subscribe to ScriptSwitch only. Authorised users need to be logged in to read this content.

Healthcare professionals working in organisations that subscribe to ScriptSwitch may register to request access – please submit your details via the ‘register’ link at the top of this page.

Type 1 and 2 diabetes: new meta-analysis quantifies risks of smoking (Dec-15)

This content is available to authorised users only.
Authorised users need to be logged in to read this content.

Type 2 diabetes: potential cardiovascular and mortality benefits with empagliflozin treatment in high-risk individuals (Oct-15)

This content is available to authorised users only.
Authorised users need to be logged in to read this content.

Type 2 Diabetes: educational programme reduces inappropriate self-monitoring of blood glucose in type 2 diabetes (July 2015)

This content is available to authorised users only.
Authorised users need to be logged in to read this content.

Type 2 Diabetes: large RCT finds no effect of sitagliptin on the risk of cardiovascular events in people with type 2 diabetes and cardiovascular disease (July-15)

This content is available to authorised users only.
Authorised users need to be logged in to read this content.

NPC Archive Item: What are the DVLA blood glucose monitoring requirements for people with diabetes?

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 19th March 2012 This Rapid Review aims to clarify the DVLA requirements and advice for the monitoring of blood glucose in people with diabetes. It is based on the […]

NPC Archive Item: Insulin analogues cost NHS millions

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 24 October 2011 A UK study found that if all analogue insulin dispensed in the UK between 2000 and 2009 had been for human insulin alternatives, the NHS would […]